| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,115,741 | 17 | 100 |
| Stuglik Brian M | director | 0 | $0 | 1 | $58,311 | $-58,311 |
| Dorval Allison | director | 0 | $0 | 1 | $83,579 | $-83,579 |
| MILLER MICHAEL PATRICK | director | 0 | $0 | 1 | $97,228 | $-97,228 |
| HUNT DOUGLAS M | See Remarks | 0 | $0 | 3 | $122,601 | $-122,601 |
| WILSON TROY EDWARD | director | 0 | $0 | 2 | $123,248 | $-123,248 |
| NOUGUES MAXIMO F | Chief Financial Officer | 0 | $0 | 3 | $141,743 | $-141,743 |
| MOYES JAY M | director | 0 | $0 | 1 | $158,796 | $-158,796 |
| Senderowicz Adrian | director | 0 | $0 | 1 | $194,311 | $-194,311 |
| Cesano Alessandra | director | 0 | $0 | 1 | $566,994 | $-566,994 |
| AUERBACH ALAN H | President and CEO | 0 | $0 | 3 | $568,929 | $-568,929 |
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. …
Over the last 12 months, insiders at Puma Biotechnology, Inc. have bought $0 and sold $2.12M worth of Puma Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Puma Biotechnology, Inc. have bought $0 and sold $1.14M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 56 shares for transaction amount of $4,619 was made by BRYCE RICHARD PAUL (SR VP, CLINICAL RESEARCH & DEV) on 2014‑04‑11.
| 2026-09-14 | Sale | Cesano Alessandra | director | 62,150 0.1218% | $9.12 | $566,994 | +8.86% | |
| 2026-09-14 | Sale | WILSON TROY EDWARD | director | 5,000 0.0098% | $9.10 | $45,500 | +8.86% | |
| 2026-07-06 | Sale | AUERBACH ALAN H | President and CEO | 44,058 0.087% | $8.26 | $364,051 | +12.53% | |
| 2026-07-06 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 9,386 0.0185% | $8.26 | $77,557 | +12.53% | |
| 2026-07-06 | Sale | HUNT DOUGLAS M | See Remarks | 8,460 0.0167% | $8.26 | $69,905 | +12.53% | |
| 2026-06-12 | Sale | Stuglik Brian M | director | 8,100 0.0156% | $7.20 | $58,311 | +24.42% | |
| 2026-06-12 | Sale | Dorval Allison | director | 11,610 0.0224% | $7.20 | $83,579 | +24.42% | |
| 2026-06-12 | Sale | WILSON TROY EDWARD | director | 10,800 0.0208% | $7.20 | $77,748 | +24.42% | |
| 2026-06-12 | Sale | MOYES JAY M | director | 22,000 0.0426% | $7.22 | $158,796 | +24.42% | |
| 2026-06-12 | Sale | Senderowicz Adrian | director | 27,000 0.0521% | $7.20 | $194,311 | +24.42% | |
| 2026-01-07 | Sale | AUERBACH ALAN H | President and CEO | 18,012 0.0358% | $5.88 | $105,893 | +23.81% | |
| 2026-01-07 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 6,405 0.0127% | $5.88 | $37,655 | +23.81% | |
| 2026-01-07 | Sale | HUNT DOUGLAS M | See Remarks | 5,014 0.01% | $5.88 | $29,477 | +23.81% | |
| 2026-01-06 | Sale | AUERBACH ALAN H | President and CEO | 16,938 0.0331% | $5.84 | $98,986 | +28.58% | |
| 2026-01-06 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 4,540 0.0089% | $5.84 | $26,532 | +28.58% | |
| 2026-01-06 | Sale | HUNT DOUGLAS M | See Remarks | 3,973 0.0078% | $5.84 | $23,218 | +28.58% | |
| 2025-11-11 | Sale | MILLER MICHAEL PATRICK | director | 20,000 0.0322% | $4.86 | $97,228 | +39.88% | |
| 2025-07-18 | Sale | Cesano Alessandra | director | 27,000 0.0539% | $3.37 | $90,909 | +78.97% | |
| 2025-07-09 | Sale | AUERBACH ALAN H | President and CEO | 21,580 0.0427% | $3.54 | $76,285 | +66.67% | |
| 2025-07-09 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 3,935 0.0078% | $3.54 | $13,910 | +66.67% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 10 percent owner | 3696580 7.1611% | $37.78M | 21 | 9 | +98.94% |
| Malley Thomas | director | 156551 0.3033% | $1.6M | 4 | 0 | +51.73% |
| BRYCE RICHARD PAUL | SEE REMARKS | 121662 0.2357% | $1.24M | 2 | 39 |
$10,154,205 | 103 | -4.60% | $631.34M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$8,866,498 | 28 | 33.64% | $474.26M |
| Increased Positions | 83 | +62.88% | 4M | +12.57% |
| Decreased Positions | 52 | -39.39% | 3M | -9.79% |
| New Positions | 33 | New | 894,428 | New |
| Sold Out Positions | 14 | Sold Out | 1M | Sold Out |
| Total Postitions | 163 | +23.48% | 35M | +2.78% |
| Acorn Capital Advisors, Llc | $23,838.00 | 8.26% | 4.13M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $21,301.00 | 7.38% | 3.69M | -14,732 | -0.4% | 2025-09-30 |
| Blackrock, Inc. | $20,644.00 | 7.16% | 3.58M | -257,838 | -6.72% | 2025-09-30 |
| Renaissance Technologies Llc | $12,412.00 | 4.3% | 2.15M | +276,500 | +14.75% | 2025-09-30 |
| Acadian Asset Management Llc | $11,848.00 | 4.11% | 2.05M | +45,159 | +2.25% | 2025-09-30 |
| American Century Companies Inc | $8,558.00 | 2.97% | 1.48M | +140,913 | +10.5% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $7,339.00 | 2.54% | 1.27M | +121,838 | +10.59% | 2025-09-30 |
| Geode Capital Management, Llc | $5,675.00 | 1.97% | 983,522 | +11,848 | +1.22% | 2025-09-30 |
| Russell Investments Group, Ltd. | $5,566.00 | 1.93% | 964,693 | +964,673 | +4.82M% | 2025-09-30 |
| Connor, Clark & Lunn Investment Management Ltd. | $5,444.00 | 1.89% | 943,472 | +43,216 | +4.8% | 2025-09-30 |